RT Journal Article
SR Electronic
T1 A systematic review and meta-analysis on the rate of human schistosomiasis reinfection
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.07.18.20156703
DO 10.1101/2020.07.18.20156703
A1 Zacharia, Abdallah
A1 Mushi, Vivian
A1 Makene, Twilumba
YR 2020
UL http://medrxiv.org/content/early/2020/07/21/2020.07.18.20156703.abstract
AB Background While praziquantel mass drug administration is currently the most widely used method in the control of human schistosomiasis, it does not prevent subsequent reinfection hence persistent transmission. Towards schistosomiasis elimination, understanding the reinfection rate is crucial in planning for the future interventions. However, there is scarcity information on the global schistosomiasis reinfection rate.Objective This systematic review and meta-analysis aimed at summarizing studies that estimated the human schistosomiasis reinfection rate.Materials and methods The protocol for this review was prepared to guide authors throughout the process. However, registration was not sought. Three data bases (PubMed, Hinari and Google Scholar) were thoroughly searched to retrieve original research articles presenting data on human schistosomiasis reinfection rate. Study quality and risk of bias was assessed based on Joanna Briggs Institute critical appraisal checklist. Meta-analysis was conducted using statistical R version 3.6.2 and R Studio using “meta” and “metafor” packages. Heterogeneity and publication bias of the studies were determined using Q – test and Egger’s regression test respectively. Random effect model was employed to estimate pooled reinfection rates.Results A total of 29 studies met inclusion criteria to be included in this review. All studies had at least satisfactory (5 – 9 scores) quality. The overal calculated and pooled schistosomiasis reinfection rates were 36.1% (±23.3%) and 33.2% (95% CI, 26.5 – 40.5%) respectively. For intestinal schistosomiasis, the calculated and pooled reinfection rates were 43.9% (±20.6%) and 43.4% (95% CI, 35.8 – 51.4%), and that for urogenital schistosomiasis were 17.6% (±10.8%) and 19.4% (95% CI, 12.3% – 29.2%) respectively. Results of subgroup analysis showed that, the type of Schistosoma species, participants age group, sample size and geographical area had influence on disparity variation in Schistosomiasis reinfection rate (p < 0.05).Conclusion Despite the control measures in place, the re-infection rate was still high, specifically on intestinal schistosomiasis as compared to urogenital schistosomiasis. Achieving 2030 sustainable development goal 3 on good health and wellbeing through schistosomiasis elimination and intensive programmatic strategies should be implemented. Among such strategies to be used at national level are repeated mass drug administration at least every six month, intensive snails control and health education.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe authors declare that no financial support was secured for this research workAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Study is not clinical trialAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data used to support the findings of this study are available from the corresponding author upon request